Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR
Ting Huang, Jinfeng Cai, Peipei Wang, Jiasheng Zhou, Haitao Zhang, Ziqi Wu, Jiacong Zhao, Zhanlian Huang, Kai Deng
Abstract
T cells and does not induce severe cytotoxicity and cell dysfunction. Mechanistically, ponatinib suppresses proviral HIV-1 transcription by inhibiting the activation of the AKT-mTOR pathway, which subsequently blocks the interaction between key transcriptional factors and the HIV-1 long terminal repeat (LTR). In summary, we discovered a novel latency-promoting agent, ponatinib, which could have promising significance for future applications of HIV-1 functional cure.
Topics & Concepts
PonatinibSAMHD1Gene silencingProtein kinase BPI3K/AKT/mTOR pathwayBiologyViral replicationVirus latencyVirologyImmunologyCancer researchReverse transcriptaseCell biologySignal transductionVirusGeneticsRNATyrosine kinaseDasatinibGeneHIV Research and TreatmentImmune Cell Function and InteractionHIV/AIDS drug development and treatment